Journal
HEMOGLOBIN
Volume 30, Issue 2, Pages 229-238Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/03630260600642559
Keywords
thalassemia; iron chelator; heart failure
Categories
Ask authors/readers for more resources
This study tries to compare the cardioprotective effects of the desferrioxamine (DFO) and deferiprone (L1) therapies on thalassemia major Patients. We enrolled nine patients with thalassemia major complicated by some degree of myocardial dysfunction. These patients, recipients of > 10 years of DFO injection therapy, were switched from or DFO to L1. Echocardiographic measures of left ventricular systolic, diastolic and global functions, were assessed regularly every 6 months. Mean values of each parameter for the DFO and L1 treatment periods were compared. using paired t-test and Wilcoxon signed-rank test. Global cardiacfunction. improved significantly. Myocardial dysfunction in patients with thalassemia major can be reversed by regular use of the oral iron chelator L1.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available